SG11202113297RA - Leader sequence - Google Patents

Leader sequence

Info

Publication number
SG11202113297RA
SG11202113297RA SG11202113297RA SG11202113297RA SG11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA SG 11202113297R A SG11202113297R A SG 11202113297RA
Authority
SG
Singapore
Prior art keywords
pvc
effector
seq
payload
leader sequence
Prior art date
Application number
SG11202113297RA
Other languages
English (en)
Inventor
Nicholas R Waterfield
Joseph Healey
Alexia Hapeshi
Original Assignee
Univ Warwick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Warwick filed Critical Univ Warwick
Publication of SG11202113297RA publication Critical patent/SG11202113297RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SG11202113297RA 2019-06-07 2020-06-05 Leader sequence SG11202113297RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1908155.3A GB201908155D0 (en) 2019-06-07 2019-06-07 Leader sequence
PCT/GB2020/051380 WO2020245611A1 (en) 2019-06-07 2020-06-05 Leader sequence

Publications (1)

Publication Number Publication Date
SG11202113297RA true SG11202113297RA (en) 2021-12-30

Family

ID=67386182

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113297RA SG11202113297RA (en) 2019-06-07 2020-06-05 Leader sequence

Country Status (12)

Country Link
US (1) US20230076614A1 (https=)
EP (1) EP3980545A1 (https=)
JP (2) JP7748288B2 (https=)
KR (1) KR20220133757A (https=)
CN (1) CN114008205A (https=)
AU (1) AU2020288380A1 (https=)
BR (1) BR112021024592A2 (https=)
CA (1) CA3142462A1 (https=)
GB (1) GB201908155D0 (https=)
MX (1) MX2021015121A (https=)
SG (1) SG11202113297RA (https=)
WO (1) WO2020245611A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158486A2 (en) * 2022-02-15 2023-08-24 The Broad Institute, Inc. Cell-type specific targeting contractile injection system
WO2024003387A1 (en) 2022-06-30 2024-01-04 Københavns Universitet Contractile injection system and use thereof
CN119735656A (zh) * 2023-09-22 2025-04-01 北京朝赛蕴生物科技有限公司 一种蛋白复合物的制备纯化及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP2964240B1 (en) * 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
WO2017066479A1 (en) * 2015-10-14 2017-04-20 Bayer Cropscience Lp Axmi554 delta-endotoxin gene and methods for its use

Also Published As

Publication number Publication date
BR112021024592A2 (pt) 2022-01-18
US20230076614A1 (en) 2023-03-09
JP2025114573A (ja) 2025-08-05
JP2022535283A (ja) 2022-08-05
GB201908155D0 (en) 2019-07-24
AU2020288380A1 (en) 2022-01-06
CN114008205A (zh) 2022-02-01
EP3980545A1 (en) 2022-04-13
MX2021015121A (es) 2022-03-17
KR20220133757A (ko) 2022-10-05
JP7748288B2 (ja) 2025-10-02
WO2020245611A1 (en) 2020-12-10
CA3142462A1 (en) 2020-12-10

Similar Documents

Publication Publication Date Title
Brunet et al. The type VI secretion TssEFGK-VgrG phage-like baseplate is recruited to the TssJLM membrane complex via multiple contacts and serves as assembly platform for tail tube/sheath polymerization
US10131888B2 (en) Intracellular protein delivery
Bagheri et al. Mode of action of cationic antimicrobial peptides defines the tethering position and the efficacy of biocidal surfaces
Hayward et al. Membrane fusion activity of purified SipB, a Salmonella surface protein essential for mammalian cell invasion
Lehr et al. C‐terminal amino acid residues of the trimeric autotransporter adhesin YadA of Yersinia enterocolitica are decisive for its recognition and assembly by BamA
Vigneux et al. The xaxAB genes encoding a new apoptotic toxin from the insect pathogen Xenorhabdus nematophila are present in plant and human pathogens
JP2025114573A (ja) リーダー配列
Barrero‐Tobon et al. Flagellar biosynthesis exerts temporal regulation of secretion of specific C ampylobacter jejuni colonization and virulence determinants
Koo et al. Functional mapping of PilF and PilQ in the Pseudomonas aeruginosa type IV pilus system
Zhao et al. Nisin-and ripcin-derived hybrid lanthipeptides display selective antimicrobial activity against Staphylococcus aureus
González-Magaña et al. The P. aeruginosa effector Tse5 forms membrane pores disrupting the membrane potential of intoxicated bacteria
Guo et al. Lipidated variants of the antimicrobial peptide nisin produced via incorporation of methionine analogs for click chemistry show improved bioactivity
US20240254169A1 (en) Protein and peptide delivery systems and methods for making and using them
CN107022001A (zh) 一种分离的母乳内源性抗菌多肽及其应用
McPherson et al. ExsB, an unusually highly phosphorylated protein required for the stable attachment of the exosporium of Bacillus anthracis
CN114908077A (zh) 噬菌体裂解酶、其嵌合物及应用
Velázquez et al. Tke5 is a novel Pseudomonas putida toxin that depolarises membranes killing plant pathogens
Taylor et al. Prophages block cell surface receptors to ensure survival of their viral progeny
US10329330B2 (en) JC polyomavirus VLP (virus-like particle) with a targeting peptide
KR20210066752A (ko) 신규한 세포막 투과성 단백질 및 이의 용도
Steiner-Rebrova et al. N-terminal toxin signal peptides efficiently load therapeutics into a natural nano-injection system
US20220290114A1 (en) Antimicrobial endolysin polypeptides, compositions and formulations
US20260015391A1 (en) Compositions for hypervesiculating gut microbes and therapeutic enzyme delivery and methods of use thereof
Ramirez Mechanism and Function of Membrane Homeostasis of Sortase Modulated by an Evolutionarily Conserved Protein Involved in Pilus Assembly in Actinobacteria
Chuang et al. Comparison of Tir from enterohemorrahgic and enteropathogenic Escherichia coli strains: two homologues with distinct intracellular properties